Europe Phase IV Clinical Trials Market Size, Share & COVID-19 Impact Analysis, By Deployment (In-house and Outsource), By Disease Indication (Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others), By Type (Interventional and Non-interventional), and Regional Forecast, 2023-2030

Table of Content:

1. Introduction
   1. Research Scope
   2. Market Segmentation
   3. Research Methodology
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities
   4. Market Trends
4. Key Insights
   1. Number of Phase IV Clinical Trials - by Key Countries, 2022
   2. Overview of Regulatory Scenario
   3. Overview: Use of AI in Clinical Trial Designs
   4. Impact of AI and Big Data Technology use in Clinical Trials
   5. Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
   6. Impact of COVID-19 on the Market
5. Europe Phase IV Clinical Trials Market Analysis, Insights and Forecast, 2019-2030
   1. Market Analysis, Insights and Forecast – By Deployment
      1. In-house
      2. Outsource
   2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Oncology
      2. Neurology
      3. Cardiology
      4. Infectious Disease
      5. Metabolic Disorder
      6. Renal/Nephrology
      7. Others
   3. Market Analysis, Insights and Forecast – By Type
      1. Interventional
      2. Non-interventional
   4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
6. Competitive Analysis
   1. Global Market Share Analysis (2022)
   2. Company Profiles (Overview, Services, SWOT analysis, Recent developments, strategies, financials (based on availability))
      1. IQVIA Inc.
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      2. Parexel International (MA) Corporation
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      3. ICON plc
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      4. Laboratory Corporation of American Holdings
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      5. Charles River Laboratories
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      6. PHASTAR
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      7. PSI
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      8. MedpaceHoldings, Inc.
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      9. Worldwide Clinical Trials
         1. Overview,
         2. Services,
         3. SWOT analysis,
         4. Recent developments,
         5. strategies,
         6. financials (based on availability)
      10. ProRelix Services LLP
          1. Overview,
          2. Services,
          3. SWOT analysis,
          4. Recent developments,
          5. strategies,
          6. financials (based on availability)
      11. Sofpromed  
          1. Overview,
          2. Services,
          3. SWOT analysis,
          4. Recent developments,
          5. strategies,
          6. financials (based on availability)

List of Figures

Figure 01: Europe Phase IV Clinical Trials Market Revenue Breakdown (USD billion, %) by Region, 2022 & 2030

Figure 02: Europe Phase IV Clinical Trials Market Value Share (%), By Deployment, 2022 & 2030

Figure 03: Europe Phase IV Clinical Trials Market Value Share (%), By Disease Indication, 2022 & 2030

Figure 04: Europe Phase IV Clinical Trials Market Value Share (%), By Type, 2022 & 2030

Figure 05: Europe Phase IV Clinical Trials Market Value (USD billion), By Country/Sub-region, 2022 & 2030

Figure 06: Europe Phase IV Clinical Trials Market Share (%), 2022

List of Tables: 

Table 01: Europe Phase IV Clinical Trials Market Revenue (USD billion) Forecast, By Deployment, 2019–2030

Table 02: Europe Phase IV Clinical Trials Market Revenue (USD billion) Forecast, By Disease Indication, 2019–2030

Table 03: Europe Phase IV Clinical Trials Market Revenue (USD billion) Forecast, By Type, 2019–2030

Table 04: Europe Phase IV Clinical Trials Market Revenue (USD billion) Forecast, By Country/Sub-region, 2019–2030